New Drug Indication Approvals

New drug indication approval - May 2025

Audiences

Healthcare professional

Industry member

Product type

Therapeutic Products

15 May 2025

This article has been migrated from an earlier version of the site and may display formatting inconsistencies.

For the most updated information related to registered therapeutic products, please refer to the Register of Therapeutic Products.

Drug caption

Product Name	TAGRISSO TABLET 40MG, TAGRISSO TABLET 80MG
Active Ingredient (Strength)	Osimertinib mesylate 47.7mg eqv Osimertinib(40mg), Osimertinib mesylate 95.4mg eqv Osimertinib(80mg)
Product Registrant	ASTRAZENECA SINGAPORE PTE LTD
Date of Approval	13/05/2025
Indications: TAGRISSO (osimertinib) as monotherapy is indicated for the treatment of patients with locally advanced, unresectable (stage III) NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations and whose disease has not progressed during or following platinum-based chemoradiation therapy. *Evaluated as part of Project Orbis.

Drug caption

Product Name	ENHERTU POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL
Active Ingredient (Strength)	Trastuzumab deruxtecan(100 mg/vial)
Product Registrant	ASTRAZENECA SINGAPORE PTE LTD
Date of Approval	29/05/2025
Indications: ENHERTU as a monotherapy is indicated for the treatment of adult patients with unresectable or metastatic hormone receptor-positive HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer who have received at least one endocrine therapy in the metastatic setting.

Drug caption

Product Name	REBLOZYL POWDER FOR SOLUTION FOR INJECTION 25 MG/VIAL, REBLOZYL POWDER FOR SOLUTION FOR INJECTION 75 MG/VIAL
Active Ingredient (Strength)	Luspatercept(25 MG/vial), Luspatercept(75.0 MG/vial)
Product Registrant	BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD.
Date of Approval	19/05/2025
Indications: Reblozyl is indicated in adults for the treatment of anemia associated with transfusion-dependent and non-transfusion-dependent beta-thalassaemia (see section 5.1).

Drug caption

Product Name	VERASEAL SOLUTIONS FOR SEALANT, 80 MG/ML, 500 IU/ML
Active Ingredient (Strength)	Human Fibrinogen(80 mg/ml),Human Thrombin(500 IU/ml)
Product Registrant	GRIFOLS ASIA PACIFIC PTE. LTD.
Date of Approval	29/05/2025
Indications: Veraseal is indicated as supportive treatment where standard surgical techniques are insufficient. -for improvement of haemostasis -as suture support: in vascular surgery

Drug caption

Product Name	RYBREVANT CONCENTRATE FOR SOLUTION FOR INFUSION 350MG/7ML
Active Ingredient (Strength)	Amivantamab(350mg/7ml)
Product Registrant	JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD
Date of Approval	27/05/2025
Indications: RYBREVANT® is indicatedin combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal-growth factor receptor (EGFR) exon 20 insertion mutations. *Evaluated as part of Project Orbis.

Drug caption

Product Name	TRECONDI POWDER FOR SOLUTION FOR INFUSION 1 G PER VIAL, TRECONDI POWDER FOR SOLUTION FOR INFUSION 5 G PER VIAL
Active Ingredient (Strength)	Treosulfan(1 g / vial), Treosulfan(5 g / vial)
Product Registrant	LINK HEALTHCARE SINGAPORE PTE LTD
Date of Approval	13/05/2025
Indications: Treosulfan in combination with fludarabine is indicated as part of conditioning treatment prior to allogeneic haematopoietic stem cell transplantation (alloHSCT) in adult patients with acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS) at increased risk of toxicity with standard conditioning therapies, and in paediatric patients older than one month with malignant and non-malignant diseases.

Drug caption

Product Name	VFEND FILM-COATED TABLET 50 MG, VFEND FOR INFUSION 200 MG/VIAL, VFEND POWDER FOR ORAL SUSPENSION 40MG/ML, VFEND FILM-COATED TABLET 200 MG
Active Ingredient (Strength)	Voriconazole(50 mg), Voriconazole(10 mg/ml), Voriconazole(40mg/ml), Voriconazole(200 mg)
Product Registrant	PFIZER PRIVATE LIMITED
Date of Approval	21/05/2025
Indications: Prophylaxis in patients who are at high risk of developing invasive fungal infections, such as haematopoietic stem cell transplant (HSCT) recipients.

Drug caption

Product Name	TALZENNA CAPSULE 0.25MG
Active Ingredient (Strength)	Talazoparib tosylate eqv Talazoparib(0.25 mg)
Product Registrant	PFIZER PRIVATE LIMITED
Date of Approval	21/05/2025
Indications: TALZENNA is indicated in combination with enzalutamide for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated.

Drug caption

Product Name	PRALUENT SOLUTION FOR INJECTION IN A PRE-FILLED PEN 75MG/ML, PRALUENT SOLUTION FOR INJECTION IN A PRE-FILLED PEN 150 MG/ML
Active Ingredient (Strength)	Alirocumab(75 mg/ml), Alirocumab(150 mg/ml)
Product Registrant	SANOFI-AVENTIS SINGAPORE PTE. LTD.
Date of Approval	15/05/2025
Indications: Primary hypercholesterolaemia and mixed dyslipidaemia Praluent is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, and in paediatric patients 8 years of age and older with heterozygous familial hypercholesterolaemia (HeFH) as an adjunct to diet: - in combination with a statin or statin with other lipid lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin or, - alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.

Drug caption

Product Name	SARCLISA CONCENTRATE FOR SOLUTION FOR INFUSION 20MG/ML
Active Ingredient (Strength)	ISATUXIMAB(20mg/mL)
Product Registrant	SANOFI-AVENTIS SINGAPORE PTE. LTD.
Date of Approval	15/05/2025
Indications: Sarclisa is indicated in combination with bortezomib, lenalidomide, and dexamethasone, for the treatment of adult patients with newly diagnosed active multiple myeloma who are not eligible for autologous stem cell transplant (ASCT). *Evaluated via Access

Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.